Clinical Trials

541 enrolled

Breast Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 3 FDA

Breast Neoplasms

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03976362 2026-02-25

KEYLYNK-008

851 enrolled 25 charts

Tumor-Agnostic

Carcinoma

NCT05226598 2026-02-05

MK-7684A-007

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05502237 2026-01-30

STAR-121

1,021 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

524 enrolled

Triple Negative Breast Neoplasms

NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

453 enrolled

Non-Small-Cell Lung

NCT04148911 2025-12-26

EL1SSAR

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT06625320 2025-12-12

RASolute 302

501 enrolled

Pancreatic Neoplasms

NCT07071337 2025-12-11

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

430 enrolled

Breast Neoplasms

NCT07238283 2025-12-09

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

662 enrolled

First-line Treatment of Metastatic Pancreatic Cancer

NCT03257033 2025-11-14

TIGeR-PaC

190 enrolled

Locally Advanced Pancreatic Cancer

NCT06212752 2025-11-12

MK-3475A-D77

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05840211 2025-10-03

ASCENT-07

654 enrolled

Breast Neoplasms

NCT07079228 2025-09-23

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

602 enrolled

Pancreatic Neoplasms

NCT05382286 2025-09-18

ASCENT-04

443 enrolled

Triple Negative Breast Neoplasms

NCT05722015 2025-09-11

MK-3475A-D77

377 enrolled 17 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

381 enrolled 1 FDA

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06419621 2025-03-12

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

360 enrolled

Triple Negative Breast Neoplasms

NCT04956692 2024-12-03

MK-3475-A86

531 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03941093 2024-11-05

LAPIS

284 enrolled 14 charts

Pancreatic Cancer Non-resectable

NCT03594747 2024-10-26

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

360 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02775435 2024-10-08

KEYNOTE-407

559 enrolled 18 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05751850 2024-05-09

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

778 enrolled

First-line Treatment of Advanced Pancreatic Cancer

NCT04329949 2023-11-18

RELIANT

Phase 3 Terminated

43 enrolled 17 charts

Pancreatic Neoplasms

NCT02993731 2023-11-15

CanStem111P

1,134 enrolled 18 charts